Moderna, Inc. Q2 2026 Earnings Recap

Moderna's shares dropped 5.4% following Q2 as investors reacted negatively to cautious revenue guidance coupled with ongoing net losses, despite some margin improvements and pipeline progress.

Key Takeaways

• Q2 revenue was $145 million, a modest 2% increase year-over-year, coming in above guidance but reflecting continued seasonality in vaccine sales.
• The company reiterated up to 10% revenue growth for 2026 but emphasized a balanced U.S./international revenue split, signaling tempered upside.
• Net loss improved slightly to $782 million, driven by reduced clinical costs and SG&A expenses, yet cash declined by $600 million to $6.9 billion amid ongoing R&D investments.
• Cost of sales fell 22% due to manufacturing efficiencies, but the substantial negative earnings and high cash burn continue to weigh on investor sentiment.
• Pipeline advancements, including positive regulatory milestones for the seasonal flu vaccine and progress in oncology programs, provide some long-term upside potential but have not shifted near-term market skepticism.